Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292666 · ClinicalTrials.gov registry record
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
A clinical trial of Venous Thromboembolism and Anticoagulants and Bleeding Disorders, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 39,603
- Enrollment target
- 2
- Study locations
NCT03292666 is a study of Venous Thromboembolism and Anticoagulants and Bleeding Disorders that has completed, run by University of California, San Francisco. The registered enrollment target is 39,603 participants, above the 5,453-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (626% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT03292666, a study of Venous Thromboembolism and Anticoagulants and Bleeding Disorders, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 39,603 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcomes, such as quality-of-life, symptom burden, and treatment satisfaction. This information is crucial to helping clinicians and patients choose between various treatment options for venous thromboembolism in order to achieve the best possible balance between the risks, benefits, and impact on health.
Conditions Studied
Interventions
- DRUG Oral Anticoagulant
Study Locations (2)
California
- Kaiser Permanente Northern California - Oakland
- Kaiser Permanente Southern California - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39,603 participants |
| Start Date | 2010-01-01 |
| Est. Completion | 2022-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292666
The ClinicalTrials.gov registry entry for NCT03292666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 39,603 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 5,453-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (626% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Oral Anticoagulant is the first listed.
NCT03292666 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03292666 about?
NCT03292666 is a clinical study titled "Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study". The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcom...
What is the current status of trial NCT03292666?
This trial is currently completed. The enrollment target is 39,603 participants. The study started on 2010-01-01. Estimated completion is 2022-06-21.
What conditions does trial NCT03292666 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Anticoagulants and Bleeding Disorders.
What interventions are being tested in trial NCT03292666?
The interventions under investigation include: Oral Anticoagulant (DRUG).
Who is sponsoring clinical trial NCT03292666?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03292666 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RECRUITING
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
RECRUITING
-
Evaluation of the SCALED (SCaling AcceptabLE cDs)
RECRUITING
Explore more on PlainTrial
Venous Thromboembolism
All registered trials for this condition
Anticoagulants and Bleeding Disorders
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.